R
35.84
1.29 (3.73%)
| Penutupan Terdahulu | 34.55 |
| Buka | 34.95 |
| Jumlah Dagangan | 411,078 |
| Purata Dagangan (3B) | 619,377 |
| Modal Pasaran | 1,444,513,280 |
| Harga / Pendapatan (P/E Ke hadapan) | 97.09 |
| Harga / Jualan (P/S) | 10.12 |
| Harga / Buku (P/B) | 5.00 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 Nov 2024 |
| Margin Keuntungan | -23.92% |
| Margin Operasi (TTM) | -26.13% |
| EPS Cair (TTM) | -0.810 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 59.10% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 4.08% |
| Nisbah Semasa (MRQ) | 12.67 |
| Aliran Tunai Operasi (OCF TTM) | -20.99 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -13.30 M |
| Pulangan Atas Aset (ROA TTM) | -9.92% |
| Pulangan Atas Ekuiti (ROE TTM) | -13.99% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Bercampur |
| Medical Devices (Global) | Bercampur | Bercampur | |
| Stok | RxSight, Inc. | Menurun | Menaik |
AISkor Stockmoo
2.1
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 5.0 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | -2.5 |
| Purata | 2.13 |
|
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The Company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 5.08% |
| % Dimiliki oleh Institusi | 89.51% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Summit Partners Public Asset Management, Llc | 30 Sep 2024 | 687,711 |
| Gilder Gagnon Howe & Co Llc | 30 Sep 2024 | 586,523 |
| Next Century Growth Investors Llc | 30 Sep 2024 | 576,453 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 72.00 (Jefferies, 100.89%) | Beli |
| Median | 47.00 (31.14%) | |
| Rendah | 40.00 (Stifel, 11.61%) | Pegang |
| Purata | 51.50 (43.69%) | |
| Jumlah | 2 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 41.64 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Stifel | 20 Dec 2024 | 40.00 (11.61%) | Pegang | 33.66 |
| Wells Fargo | 11 Dec 2024 | 42.00 (17.19%) | Pegang | 37.58 |
| UBS | 06 Dec 2024 | 52.00 (45.09%) | Beli | 43.15 |
| Jefferies | 29 Oct 2024 | 72.00 (100.89%) | Beli | 52.16 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 02 Jan 2025 | Pengumuman | RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference |
| 07 Nov 2024 | Pengumuman | RxSight, Inc. Reports Third Quarter 2024 Financial Results |
| 24 Oct 2024 | Pengumuman | RxSight, Inc. to Report Third Quarter Financial Results on November 7, 2024 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |